<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><submitter>Ding J</submitter><funding>Fundamental Research Funds for the Central Universities</funding><funding>Natural Science Foundation of China</funding><funding>CAMS Innovation Fund for Medical Sciences</funding><pubmed_abstract>Schlafen-5 (SLFN5) is an interferon-induced protein of the Schlafen family, which are involved in immune responses and oncogenesis. To date, little is known regarding its anti-HIV-1 function. Here, the authors report that overexpression of SLFN5 inhibits HIV-1 replication and reduces viral mRNA levels, whereas depletion of endogenous SLFN5 promotes HIV-1 replication. Moreover, they show that SLFN5 markedly decreases the transcriptional activity of HIV-1 long terminal repeat (LTR) via binding to two sequences in the U5-R region, which consequently represses the recruitment of RNA polymerase II to the transcription initiation site. Mutagenesis studies show the importance of nuclear localization and the N-terminal 1-570 amino acids fragment in the inhibition of HIV-1. Further mechanistic studies demonstrate that SLFN5 interacts with components of the PRC2 complex, G9a and Histone H3, thereby promoting H3K27me2 and H3K27me3 modification leading to silencing HIV-1 transcription. In concert with this, they find that SLFN5 blocks the activation of latent HIV-1. Altogether, their findings demonstrate that SLFN5 is a transcriptional repressor of HIV-1 through epigenetic modulation and a potential determinant of HIV-1 latency.</pubmed_abstract><journal>Nucleic acids research</journal><pagination>gkac489</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9226525</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Schlafen 5 suppresses human immunodeficiency virus type 1 transcription by commandeering cellular epigenetic machinery.</pubmed_title><pmcid>PMC9226525</pmcid><funding_grant_id>81973220</funding_grant_id><funding_grant_id>2021-I2M-1-038</funding_grant_id><funding_grant_id>31870164</funding_grant_id><funding_grant_id>33320200046</funding_grant_id><funding_grant_id>2021-I2M-1-030</funding_grant_id><pubmed_authors>Cen S</pubmed_authors><pubmed_authors>Ma L</pubmed_authors><pubmed_authors>Solomon M</pubmed_authors><pubmed_authors>Ding J</pubmed_authors><pubmed_authors>Liang C</pubmed_authors><pubmed_authors>Li X</pubmed_authors><pubmed_authors>Liu Z</pubmed_authors><pubmed_authors>Wen J</pubmed_authors><pubmed_authors>Wang S</pubmed_authors><pubmed_authors>Guo F</pubmed_authors><pubmed_authors>Chen S</pubmed_authors><pubmed_authors>Wang Z</pubmed_authors><pubmed_authors>Zhao J</pubmed_authors></additional><is_claimable>false</is_claimable><name>Schlafen 5 suppresses human immunodeficiency virus type 1 transcription by commandeering cellular epigenetic machinery.</name><description>Schlafen-5 (SLFN5) is an interferon-induced protein of the Schlafen family, which are involved in immune responses and oncogenesis. To date, little is known regarding its anti-HIV-1 function. Here, the authors report that overexpression of SLFN5 inhibits HIV-1 replication and reduces viral mRNA levels, whereas depletion of endogenous SLFN5 promotes HIV-1 replication. Moreover, they show that SLFN5 markedly decreases the transcriptional activity of HIV-1 long terminal repeat (LTR) via binding to two sequences in the U5-R region, which consequently represses the recruitment of RNA polymerase II to the transcription initiation site. Mutagenesis studies show the importance of nuclear localization and the N-terminal 1-570 amino acids fragment in the inhibition of HIV-1. Further mechanistic studies demonstrate that SLFN5 interacts with components of the PRC2 complex, G9a and Histone H3, thereby promoting H3K27me2 and H3K27me3 modification leading to silencing HIV-1 transcription. In concert with this, they find that SLFN5 blocks the activation of latent HIV-1. Altogether, their findings demonstrate that SLFN5 is a transcriptional repressor of HIV-1 through epigenetic modulation and a potential determinant of HIV-1 latency.</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Jun</publication><modification>2022-07-10T02:09:17.33Z</modification><creation>2022-07-10T02:09:17.33Z</creation></dates><accession>S-EPMC9226525</accession><cross_references><pubmed>35687115</pubmed><doi>10.1093/nar/gkac489</doi></cross_references></HashMap>